Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab
– Enrollment and dosing of patients with giant cell arteritis commenced in global Phase 2 study HAMILTON, Bermuda, Jan. 03, […]
– Enrollment and dosing of patients with giant cell arteritis commenced in global Phase 2 study HAMILTON, Bermuda, Jan. 03, […]
Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid […]
— Received approval to begin multiple-ascending dose in Phase 1/2 clinical trial of MRT5005, an mRNA therapeutic for CF — […]
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into […]
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the […]
VANCOUVER, British Columbia, Jan. 03, 2019 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (“Amerigo” or the “Company”) (TSX: ARG) is pleased […]
TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (TSX: FFH and FFH.U) announces that it has declared […]
TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) — Gran Colombia Gold Corp. (TSX: GCM; OTCQX: TPRFF) announced today that its Board […]
TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) — Internet of Things Inc. (TSX VENTURE: ITT; OTC: INOTF; FRANKFURT: 7IT) (“ITT” or […]
– Kitov to receive $3.5M milestone payments and 40% – 60% of net profit on sales of Consensi ™– Coeptis […]